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Abstract: The majority of research into the effects of mesenchymal stem cell (MSC) transplants on
spinal cord injury (SCI) is performed in rodent models, which may help inform on mechanisms of
action, but does not represent the scale and wound heterogeneity seen in human SCI. In contrast,
SCI in dogs occurs naturally, is more akin to human SCI, and can be used to help address important
aspects of the development of human MSC-based therapies. To enable translation to the clinic
and comparison across species, we have examined the paracrine, regenerative capacity of human
and canine adipose-derived MSCs in vitro. MSCs were initially phenotyped according to tissue culture
plastic adherence, cluster of differentiation (CD) immunoprofiling and tri-lineage differentiation
potential. Conditioned medium (CM) from MSC cultures was then assessed for its neurotrophic
and angiogenic activity using established cell-based assays. MSC CM significantly increased neuronal
cell proliferation, neurite outgrowth, and βIII tubulin immunopositivity. In addition, MSC CM
significantly increased endothelial cell migration, cell proliferation and the formation of tubule-like
structures in Matrigel assays. There were no marked or significant differences in the capacity of
human or canine MSC CM to stimulate neuronal cell or endothelial cell activity. Hence, this study
supports the use of MSC transplants for canine SCI; furthermore, it increases understanding of how
this may subsequently provide useful information and translate to MSC transplants for human SCI.
Keywords: mesenchymal stem/stromal cell; spinal cord injury; neurotrophic activity; angiogenic
activity; translational research; regenerative medicine
1. Introduction
Much research has been performed to better understand the effects of spinal cord injury (SCI)
and it sequelae, and how best to repair the damage caused and alleviate the loss of function. However,
the absence of preclinical models that closely represent human SCI represents an important block
in progress into potential SCI therapies. There is a clear need for the further development of SCI
models that help bridge gaps between laboratory-based in vitro studies, preclinical small animal
studies and human clinical trials [1–3].
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Cell therapies for SCI require translational models to determine how they can be developed for
clinical application. Rats have most commonly been used for such work [4], but, despite advantages in
anatomical and mechanistic studies, these small animal models have a number of limitations, including
physiological differences in neuroplasticity and in their capacity to recover compared with humans.
For example, rats inflicted with a complete contusion SCI recover a capacity for weight-bearing
and some movement within 1–2 weeks of injury, as determined by observational scoring, whilst
humans can remain with a complete loss of motor function for life [5]. In addition, because SCI does not
naturally occur in rodents, the injury must be induced in a controlled laboratory setting. This benefits
analysis of specific neuronal defects, interventions and experimental reproducibility; however, it does
not address the natural heterogeneity of human SCI, or the likely heterogeneity of new treatment
outcomes [6,7].
Larger animals, such as cats, dogs and nonhuman primates, are at scale and physiologically
more akin to humans than rodents [1,2,7]. Hence, many studies have examined the effects of cell
transplantation after SCI in these larger models. Of these animals, the use of companion dogs in
particular have been seen as advantageous as these animals naturally and often suffer from SCI
as a result of degenerative disc disease and traumatic herniation of the intervertebral disc [8–11].
Furthermore, the histopathology and functional outcomes of canine SCI has been studied, with findings
showing that SCI in dogs and humans is comparable [12,13]. Therefore, cell therapy research in
naturally occurring SCI in dogs has been suggested to represent an important translational route to
enable the prospects of developing successful new treatments for human SCI [8]. There is an emerging
picture that comparison of the underlying biology in human SCI and naturally occurring canine SCI,
and of potential therapeutics in both species, is worthwhile and may be mutually beneficial.
In recent years, transplantation of mesenchymal stem cells (MSCs) has developed as a promising
candidate to abrogate the neural damage cause by SCI and help repair injured neural tissues [14–16].
The therapeutic effects of transplanted MSCs are likely due to their capacity to secrete neurotrophic,
angiogenic, anti-inflammatory and immunomodulatory factors that prevent or overcome the effects
of the nerve-inhibitory milieu in SCI lesion sites [15,17–19]. In a previous study, we reported
that humans with complete SCI maintain a population of MSCs after long-term injury that can be
cultured and increased in cell numbers [20]. Furthermore, we demonstrated that human [21,22]
and canine [23] MSCs secrete factors into cell culture-conditioned medium (MSC CM) that have
neurogenic and angiogenic effects. However, we have not directly compared this regenerative
paracrine activity of MSCs derived from humans with those from dogs. Therefore, with a view to
further informing the translation of MSC-based therapies for SCI from dogs to humans, and potentially
vice versa, this study has compared the effects of human MSC CM and canine MSC CM on established
models of neuronal and endothelial cell growth.
2. Materials and Methods
2.1. MSC Isolation and Growth
Ethical approval was gained for human MSC isolation from the excised infrapatellar fat pad of
patients undergoing knee replacement surgery, Research Ethics Committee (REC) approval number
12/EE/0136; National Research Ethics Service (NRES) Committee, East of England, Hertfordshire.
The tissue was obtained from donors with informed consent and the research was in accordance
with the Declaration of Helsinki. Institutional approval was provided for canine MSC isolation
from the University of Chester Faculty of Science and Engineering Research Ethics Committee: REC
approval number 060/16/CW/BS. Canine cells were isolated from surgically extracted inguinal fat pads
of dogs undergoing MSC transplantations for their treatment of joint pathology. Both the human MSC
and canine MSCs were isolated by collagenase digestion as described previously [23], and cultured in T75
culture flasks with Dulbecco’s Modified Eagle Medium (DMEM)/F-12 culture medium supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (standard culture medium; all from
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Gibco®, Life Technologies™, Paisley, UK). Cells were incubated at 37 ◦C in an atmosphere of 5% CO2,
95% air.
2.2. Phenotyping Human and Canine MSCs
MSC characterisation was undertaken according to the guidelines of the International Society for
Cellular Therapy, including microscopic evidence of the cells being adherent to tissue culture plastic,
demonstrating the capacity to differentiate along mesodermal lineages, and exhibiting a defined CD
immunoprofile [24]. The plastic adherence of culture-expanded cells was determined by phase contrast
microscopy, whilst the differentiation potential of MSC cultures was examined by treating cultures
with established adipogenic, osteogenic and chondrogenic induction medium [20,23], as described
below (minimum of n = 3 human and n = 3 canine donors):
2.2.1. Adipogenic Differentiation
Cells seeded in standard culture medium at a density of 104 cells/mL (1 mL/well) and allowed
to adhere in 24-well culture plates were treated for four weeks with standard culture medium
supplemented with 1 µM dexamethasone (Sigma Aldrich, Dorset, UK), 1% insulin, transferrin
and selenium (ITS; Gibco®, Life Technologies™), 0.5 µM 3-isobutyl-1-methylxanthine (IBMX; Sigma)
and 100 µM indomethacin (Sigma). Culture medium was replaced every 2–3 days. Control medium
consisted of solvent carriers, i.e., methanol and dimethylsulfoxide (DMSO), at the same dilution used
for the induction medium. After four weeks in culture, the cells were fixed and stained for the presence
of lipid accumulation using Oil Red O staining [20,23].
2.2.2. Osteogenic Differentiation
Cells seeded in standard culture medium at a density of 104 cells/mL (1 mL/well) and allowed
to adhere in 24-well culture plates were treated for four weeks with standard culture medium
supplemented with 10 µM beta-glycerophosphate, 50 µM ascorbic acid and 10 nM dexamethasone
(all Sigma), with medium replaced every 2–3 days. Control medium contained solvent carriers, i.e.,
methanol and cell culture water at the same dilution used for the induction medium. After four
weeks in culture, the cells were fixed and stained for the presence of the osteogenic marker, alkaline
phosphatase activity [20,23].
2.2.3. Chondrogenic Differentiation
Culture-expanded cells were harvested by trypsinisation and centrifugation and resuspended
in DMEM/high glucose (Gibco®, Life Technologies™) supplemented with 2% FBS and 1%
penicillin/streptomycin and aliquoted into 1.5 mL Eppendorf tubes (1ml/tube) at a final cell density
of 2.5 × 105 cells/mL. Following microcentrifugation at 500× g for 5 min, the cells formed small cell
pellets, then the medium was replaced with DMEM/high glucose supplemented with 37.5 µg/mL
ascorbate-2-phosphate (Sigma), 1% ITS, 100 nM dexamethasone and 10 ng/mL transforming growth
factor beta-1 (TGF-β1; Peprotech, New Jersey, USA), with medium replaced every 2–3 days.
Control medium contained the solvent carriers, i.e., ethanol, cell culture water and bovine serum
albumin/phosphate-buffered saline (BSA/PBS, Sigma) at the same dilution used for the induction
medium. After four weeks in culture, the pellets were fixed, embedded in paraffin and tissue sections
stained for the presence of the chondrogenic marker, glycosaminoglycan deposition, using toluidine
blue [20,23].
2.2.4. CD Immunoprofiling
The CD profiles of human MSC cultures were examined at passage IV using immunolabelling
and flow cytometry, as described previously [20]. Briefly, cells were harvested by trysinisation
and centrifugation to form cell pellets and then resuspended at a density of 5 × 105 cells/mL in 2%
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BSA/PBS. Initially, the cells were blocked with 10% normal human immunoglobulin (Ig) (Grifols,
Cambridge, UK) for 1 hr. Cells were then washed with 1ml of 2% BSA/PBS and centrifuged (1000 rpm)
to pellet before resuspending in 2% BSA/PBS at a minimum of 105 cells/mL. One of the following
phycoerythrin (PE) or fluorescein isothiocyanate (FITC) conjugated mouse monoclonal anti-human
antibodies were added to aliquots: PE-CD34, FITC-CD44, PE-CD45, PE-CD105 (Immunotools,
Friesoythe, Germany), PE-CD73 or PE-CD90 (BD Biosciences, Oxford, UK). The cells were also
incubated with isotype-matched control antibodies IgG2a and IgG1 (Immunotools) to detect nonspecific
fluorescence. The CD profiles of canine MSCs also were performed using immunolabeling and flow
cytometry at passage IV, as described previously [23]. Aliquots of cells were resuspended in 200 µL
2% BSA/PBS, then incubated for 30 min at room temperature with 5 µL antibodies specific for canine
antigens or validated for canine cross-reactivity against; PE-CD34 (BD Biosciences), FITC-CD44,
PE-CD45, and PE-CD90 or IgG1 mouse, IgG2a rat IgG2b rat and IgG2b (all eBiosciences, ThermoFisher
Scientific, Loughborough, UK) rat matched isotype control respectively.
After immunolabelling, cells were washed with 2% BSA/PBS and immunoreactivity for each CD
marker was performed by flow cytometry using a Beckman Coulter FC500 Flow Cytometer (Beckman
Coulter (UK) Ltd., High Wycombe, UK) and data was analyzed using Kaluza® Analysis Software.
2.3. Preparation of Conditioned Medium from Human and Canine MSC Cultures
The conditioned medium was prepared and harvested from human and canine MSCs, adapting
previously established protocols for the determination of neurotrophic and angiogenic activity [21–23].
Briefly, human or canine MSC were seeded at 1.5 × 106 cells in a T75 flask and left overnight for
adherence. Flasks were then washed three times with sterile PBS and 15 mL of serum-free DMEM/F12
medium supplemented with 1% penicillin/streptomycin was added to each flask. After three further
days of culture, conditioned medium (CM) was harvested, 0.2 µm filter sterilised (Minisart, Germany)
and stored in aliquots at −80 ◦C until used. The viability of the MSCs cultures during this 72-h
incubation remained greater than 95% (determined by trypan blue exclusion at day 3). Serum-free
nonconditioned medium that had been incubated in T75 flasks, but with no cells seeded, was generated
following the same procedure and used as a control in this study.
2.4. Assessment of the Neurotrophic Effects of Human and Canine MSC CM
SH-SY5Y neuroblastoma cells were used to examine the neurotrophic effects of human and canine
MSC CM, as reported previously [21,23]. In brief, SH-SY5Y cells were seeded in 24-well plates
in DMEM/F12 medium supplemented with 10% FBS and 1% penicillin/streptomycin at 2 × 104
cells/mL/well and left to adhere overnight. Medium was removed and replaced with either human
or canine MSC CM or control medium and placed in the Cell IQ live cell imaging platform (Cell-IQ
version 2, CM Technologies Oy, Tampere, Finland) for three days at 37 ◦C/5% CO2. Cell IQ analyser
software was used to measure total SH-SY5Y neuronal cell number and total neurite outgrowth in
each treated condition. Further examination of neural differentiation was performed via βIII tubulin
immunofluorescent staining. Briefly, SH-SY5Y cells seeded onto sterilised glass coverslips, allowed to
adhere overnight, (i) gently washed in PBS and incubated in MSC CM or control medium for three
days, (ii) fixed in 10% formalin (Sigma), then washed twice with PBS and blocked with 2% BSA/PBS
for an hour, (iii) incubated at 4 ◦C for 2 h with the primary antibody, mouse monoclonal anti-βIII
tubulin (Abcam, Cambridge, UK), (iv) washed with PBS and incubated in the dark at 4 ◦C for 1 h
with secondary antibody, rhodamine Red-X-AffiniPure donkey anti-mouse IgG (H+L) (Stratech Ltd.,
Newmarket, UK), (v) after a final wash, the coverslips were mounted with Vectashield (Vectalabs, New
South Wales, Australia) and imaged using a Leica DMI4000 digital microscope (Leica, London, UK).
2.5. Assessment of the Angiogenic Effects of Human and Canine MSC CM
EA.hy926 endothelial cells were used to determine the angiogenic effects of human and canine
MSC CM, where scratch wound assays measured endothelial cell migration and proliferation (further
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determined by MTT assay) and the formation of endothelial tubule-like structures was examined using
Matrigel assays, as reported previously [22,23].
For the scratch wound assays, EA.hy926 cells were seeded in standard culture medium into a
24-well plate and cultured in monolayers to confluence. Using a 200-µL pipette tip, each well was
scratched centrally from top to bottom, leaving a gap void of cells, then the well was washed (to remove
debris) prior to the additions of MSC CM or control medium. The plates were then incubated in Cell
IQ live cell imaging platform for two days at 37 ◦C/5% CO2. The percentages of scratch closure wound
area, endothelial cell migration, and the numbers of dividing cells were measured over this time course
using the Cell IQ analyzer software.
To assay endothelial tubule formation, a substrate of reduced growth factor Matrigel (Corning,
USA) was established in 96-well plates then EA.hy926 cells were seeded at 2 × 104 cells/well in 200 µL
of either human or canine MSC CM or control medium and the plates incubated at 37 ◦C/5% CO2.
After this time, total endothelial tubule length and the numbers of tubule branch points were measured
using the Cell IQ platform and analyzer software.
2.6. Assessment of Viable Cell Proliferation Using MTT Assays
The proliferation of viable SH-SY5Y and EA.hy926 cells was examined following culture with
human and canine MSC CM or control medium, for three and two days, respectively, using MTT assay
(Sigma), as previously described [22,23].
2.7. Statistical Analysis
Data were generated from MSC cultures established from at least three human donors and three canine
donors and have been reported as means ± standard error of the means (SEM). For statistical analysis,
p ≤ 0.05 was considered as a significance threshold, which was determined using one-way or two-way
ANOVAs with Tukey’s multiple comparison post-hoc test in GraphPad Prism 7 (GraphPad Software).
3. Results
3.1. Phenotypic Characterisation of Human and Canine MSC Cultures
The human and canine cells isolated and culture-expanded from adipose tissue fulfilled the criteria
previously proposed by the International Society for Cellular Therapy (ISCT) to be considered
MSCs [24]. These cell cultures consisted only of plastic-adherent cells with a fibroblastic appearance,
which demonstrated the differentiation potential to form adipocytes, osteoblasts, and chondrocytes.
After adipogenic induction, intracellular lipid droplet accumulation was confirmed by Oil Red O
staining, whilst alkaline phosphatase activity was present when cells cultured in osteogenic induction
medium, and the accumulation of glycosaminoglycans (GAGs) in the extracellular matrix of cell pellets
were seen when cultured in chondrogenic induction medium, as indicated by toluidine blue staining
(Figure 1a,b). Following analysis by flow cytometry, the human and canine cell cultures showed a
lack of immunoreactivity for the hematopoietic CD markers, i.e., CD34 and CD45, while showing
immunopositivity for the MSC-associated markers, i.e., CD44 and CD90, with each marker being
detected in greater than 90% of all cell populations (Figure 1c).
3.2. The Neurotrophic Effects of Human and Canine MSC CM on SH-SY5Y Neuronal Cells
There was a marked increase in the numbers of SH-SY5Y neuronal cells present and in the extension
of neurites from these cells when cultured for three days in human and canine MSC CM compared to
those SH-SY5Y cells cultured in control medium (Figure 2a). Culturing SH-SY5Y cells in either human
or canine MSC CM also increased βIII tubulin immunoreactivity compared to control conditions
(Figure 2b). Automated image analysis was used to measure SH-SY5Y cell numbers, SH-SY5Y neurite
outgrowth and the proportions of βIII tubulin immunopositive cells. This demonstrated that whilst
both human and canine MSC CM significantly and markedly increased each of these parameters
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compared to the control medium, there were no significant differences between human versus canine
MSC CM (Figure 2c). There were similarly increased absorbance levels detected by MTT assays of
SH-SY5Y cell cultures in human and canine MSC CM compared to the control medium (Figure 2c, upper
right panel). The MTT assay detects metabolic activity in viable cells. Given the increased numbers of
SH-SY5Y cells seen in MSC CM this increased absorbance is supportive of the MSC CM increasing
the numbers of viable cells present, although it may also indicate increased metabolic activity.
Figure 1. Phenotypic characterization of human and canine mesenchymal stem cells (MSCs). (a) Human
MSCs were plastic adherent with a fibroblastic morphology under phase-contrast microscopy (top left
panel). Following induction, human MSCs showed Oil Red O positivity, alkaline phosphatase positivity
and secreted a toluidine blue-stained cartilaginous extracellular matrix, indicating their differentiation
potential to form adipocytes, osteoblasts and chondrocytes, respectively (as indicated). (b) Canine MSCs
exhibited a similar phenotype, although their propensity to differentiate to form Oil Red O positive
adipocytes was less marked. Scale bars = 50 µm. (c) Representative histograms of flow cytometric
analysis of human (top panels) and canine (bottom panels) MSCs following immunocytochemical
staining for CD34, CD44, CD45 and CD90. Immunoreactivity with irrelevant isotype-matched control
antibodies is shown in blue, while immunoreactivity for each of the CD markers is shown in red.
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Figure 2. Human and canine MSC conditioned medium increased SH-SY5Y cell proliferation,
βIII tubulin immunopositivity and neurite outgrowth to a similar extent. (a) Representative images are
shown of SH-SY5Y neuronal cells under phase-contrast microscopy following culture for three days
in human MSC conditioned medium (human MSC CM), canine MSC conditioned medium (canine
MSC CM), or control medium. As shown, there was enhanced cell numbers and neurite outgrowth
(arrowed) in both human and canine MSC CM compared with control cultures. Scale bars = 200 µm.
(b) Representative fluorescence images of SH-SY5Y cells after three days of culture in human MSC
CM, canine MSC CM or control medium following immunocytochemical staining for the neuronal
marker, βIII tubulin. As shown, βIII tubulin immunopositive cells were seen in human and canine
MSC CM to a much greater extent than in control conditions. (c) (top panels) Image analysis software
demonstrated significantly increased SH-SY5Y cell numbers in the presence of human and canine MSC
CM compared to control medium after three days in culture (top left) as well as increased metabolic
activity as determined by MTT assays (top right); (bottom panels) there were significant increases
the proportions of βIII tubulin immunopositive cells in human and canine MSC CM compared to
the control medium, as well as increased neurite length. * p ≤ 0.05, ** p ≤ 0.01, ns = nonsignificant.
Data shown as means ± SEM, with a minimum of three independent experiments.
3.3. The Angiogenic Effects of Human and Canine MSC CM on EA.hy926 Endothelial Cells
Assessment of the effects of MSC CM on EA.hy926 endothelial cells using automated image
analysis of the scratch wound assay included three parameters; scratch wound closure, cell movement
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tracking and the numbers of dividing cells present over a 2-day period (Figure 3a). Human and canine
MSC CM significantly promoted scratch wound closure when compared with the control medium
(p ≤ 0.0001 and p ≤ 0.05, respectively). In addition, tracking individual EA.hy926 cell movement
demonstrated that both human and canine MSC CM increased endothelial cell movements towards
the centre of scratch area, when compared with the control medium (both p ≤ 0.0001). Furthermore,
the number of dividing cells within the scratch area also showed significant increases when cultured in
human and canine MSC CM compared with culture in the control medium (p ≤ 0.0001). MTT assays
of EA.hy926 endothelial cell cultures indicated significantly increased absorbance levels in human
and canine MSC CM compared to the control medium, which may be due to increased cell proliferation
(as more dividing cells in scratch wound assay were seen by image analysis) and/or increased metabolic
activity (Figure 3a, bottom right panel). There were no significant differences in any of these parameters
between the effects of human MSC CM versus canine MSC CM.
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and proliferation and induced the formation of endothelial tubule-like structures in Matrigel assays.
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(a) Representative images are shown under phase-contrast microscopy of EA.hy926 endothelial cell
scratch wound assays. Image analysis of digitized images collected every 15 min over a two-day period
demonstrated that scratch wound closure and endothelial cell migration was markedly greater in
the presence of human and canine MSC CM versus control medium, with no significant difference seen
between human and canine MSC CM (top graphs). Further image analysis (left lower panel) showed a
significant increase in the numbers of dividing EA.hy926 cells in the presence of human and canine MSC
CM compared to the control medium. In addition, there was increased metabolic activity in MSC CM
treated cultures compared to control cultures (lower right panel). Scale bars = 200µm. (b) Representative
phase-contrast images are shown of EA.hy926 endothelial cells cultured on Matrigel in the presence of
human MSC CM or canine MSC CM versus control medium. (Bottom panels) Significant increases were
observed in both the total endothelial tubule length (per image) and the total number of endothelial
branch points in EA.hy926 cultures treated with human and canine MSC CM compared to the control
medium. For all panels, * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001, ns = nonsignificant. Scale bars = 200 µm.
Data are shown as means ± SEM, with a minimum of three independent experiments.
Assessment of EA.hy926 cells forming endothelial tubule-like structures in Matrigel assays was
quantified using automated image analysis to count the total length of formed tubule-like structures
and the total number of tubule branch points from digitised images. EA.hy926 cells cultured for 1 day
in human and canine MSC CM had increased their formation of tubule-like structures compared to
culture in control medium, where there were no tubule-like structures present (Figure 3b). There were
significant increases in both the total tubule length and branch point formations in human and canine
MSC CM when compared with control medium (both p ≤ 0.01 and p ≤ 0.05, respectively). There were
no significant differences in these parameters in human MSC CM versus canine MSC CM.
4. Discussion
Currently, there is no cure for SCI, but recent research on cell-based therapies has shown
encouraging results, promising improvement in some lost functional activity. MSCs are largely
investigated both for their feasibility to treat SCI as an autologous cell transplant and because of their
capacity to secrete an array of bioactive molecules, including growth factors and anti-inflammatory
or immunomodulatory cytokines that prevent tissue damage and enhance wound healing [14,17–19].
There is, however, a clear need of an animal model that reflects specific problems of human SCI,
including aspects of wound heterogeneity and scale-up issues, e.g., to determine therapeutic doses
and optimised delivery of cell transplants. Other researchers have used natural SCI in dogs as a means
to inform future cell therapies in humans, as well as developing new treatment options in veterinary
medicine. Hence, SCI in dogs has been treated with autologous olfactory ensheathing cells [25]
and MSCs [26], the latter study being completed by researchers who further trialed the treatment
of human SCI with autologous MSC transplants [27] where both the canine and human recipients
demonstrated improved functional outcomes. The emergence of naturally occurring SCI in companion
dogs as a model for new treatments of humans with SCI is now recognised within the field [8–10,12].
In this study, we directly compared the neurogenic and angiogenic capacity of human
adipose-derived MSCs with their canine counterparts to better understand similarities or differences
between the two species. We found that adipose-derived human and canine MSCs have a similar
phenotype that largely matches that proposed by the ISCT to be considered MSCs [24]. The extent to
which canine MSCs underwent adipocyte differentiation was poor compared to human MSCs; however,
this could be attributed to the induction medium, which followed a protocol established for human
cells [20], and previously used in our laboratory for canine cells [23], rather than developed specifically
for canine cells [28]. This method was to minimize laboratory-based experimental variation, but also
because the focus of our research was to compare paracrine activity, not MSC differentiation potential.
Importantly, we found that the neurogenic and angiogenic effects of MSC CM from human and canine
MSC cultures were comparable and both increased SH-SY5Y neuronal proliferation, βIII tubulin
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immunoreactivity and neurite outgrowth, and EA.hy926 endothelial cell proliferation, migration
and the formation of endothelial tubule-like structures, to a significantly greater extent than control
medium, indicating marked trophic activity. The neurogenic [19,21] and angiogenic [22,29] effects
of human MSC CM have been well documented, with much research showing that MSCs secrete
neuroprotective, neurotrophic, angiogenic and immunomodulatory factors that are likely to inhibit
the damage and increase repair after SCI [reviewed in 17]. Recently, a comprehensive proteomic
determination of the content of canine MSC CM similarly demonstrated the secretion of a wide variety
of trophic and immunomodulatory factors [30]. Furthermore, other research has shown that canine
bone marrow MSCs secrete neurotrophic factors and angiogenic factors into the conditioned medium,
which promoted angiogenesis using the chorioallantoic membrane assay [31]. Transplantation of
canine MSCs into dogs with SCI also was associated with their expression of neurotrophic factors
in vivo [32] and increased neural regeneration [33] and functional recovery after SCI [33–35]. In a recent
study, injections with canine MSC CM was similarly associated with increased functional recovery in
SCI dogs [36]. Hence, our data, combined with these earlier studies, support the hypothesis that canine
MSCs are trophic cells that have application in wound healing and tissue regeneration, and hence a
comparison of the paracrine activity of human and canine MSCs is useful when considering how these
cells may function following transplantation after SCI.
The current study suggests that the effects of human and canine MSCs are likely to be maintained
across species. However, there is a caveat to this interpretation as we have used human responder
cells only, i.e., SH-SY5Y neuronal cells and EA.hy926 endothelial cells, to examine the effects of
human and canine MSC CM. This has some advantages in terms of the experimental consistency,
but it is possible that the responses of these human cells to growth factors and other factors present
in canine MSC CM do not accurately reflect the responses of canine neural and endothelial cells.
Whilst it seems likely that, if anything, there would be enhanced neurotrophic and angiogenic effects
seen if the canine MSC CM were applied to primary canine cells, it remains important to perform
this analysis. Further research also is required to examine whether the comparative trophic effects of
human and canine MSC CM seen in the cell-based assays reported herein accurately reflect what occurs
in the more complex in vivo microenvironment of the damaged CNS, requiring animal models of SCI.
5. Conclusions
In conclusion, this study has examined the paracrine effects of human and canine MSCs cultured
in identical conditions and using identical assays of neurotrophic and angiogenic activity. We have
shown that MSCs from both species have a comparable phenotype and similar marked trophic effects
on neuronal and endothelial cells. These findings may prove useful as further research examines
the outcomes of future MSC-based therapies in dogs and humans with SCI.
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